Urgent Meds

Danyelza (Naxitamab-gqgk)

  • Name: Danyelza
  • Generic Name: Naxitamab
  • Dosage Form & Strength: Injection: 40 mg/10 mL (4 mg/mL) in a single-dose vial
  • Manufactured By: Y-mAbs Therapeutics, Inc.

Danyelza is used, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat pediatric patients aged 1 year and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have a partial response, minor response, or stable disease to prior therapy.

Recommended Dosage: The recommended dosage of Danyelza injection is 3 mg/kg/day (up to 150 mg/day), administered as an intravenous infusion after dilution on Days 1, 3, & 5 of each treatment cycle. Repeat the treatment cycles every four weeks until the complete response or partial response, followed by the five additional cycles every four weeks. Subsequent treatment cycles may be repeated every eight weeks. Discontinue Danyelza dosage and GM-CSF for disease progression or unacceptable toxicity. Administer GM-CSF subcutaneously before and during each treatment cycle as recommended. 

Contact Patient Support

If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.